Diffuse large B-cell lymphoma is a disease of older adults, yet CAR-T is underutilized in these patients. (A) Surveillance, Epidemiology, and End Results Program¹² data illustrating age breakdown at diagnosis, highlighting that DLBCL predominantly affects older adults, with the majority (60%) aged >65 years and almost one-third aged ≥75 years. (B) Chihara et al report low real-world utilization of CAR-T in third-line or later therapy: 20% of patients aged 65 to 75 years, and 13% of those aged ≥75 years. Improving patient optimization, product selection, and toxicity management will likely lead to better outcomes for older adults and potentially reduce costs.